newsfilter
← Latest News
Business Wire·

Schrödinger Announces Discontinuation of SGR-2921 Program

Schrödinger, Inc. (NASDAQ:SDGR) today announced the discontinuation of the clinical development program for SGR-2921, its CDC7 inhibitor, which was being evaluated in a Phase 1 dose-escalation study in patients with